SCHEMBL14949302

SCHEMBL14949302

CSc1cc(Oc2cc(N)nc(N)n2)ccc1-c1nnc(Nc2cccc(C)c2)[nH]1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.37
KIT P10721 1/20 0.37
PDGFRA P16234 1/20 0.37
CDK11B P21127 1/20 0.37
FLT3 P36888 1/20 0.37
CDKL2 Q92772 1/20 0.37
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
NOD1 Q9Y239 1/20 0.33
CDK8 P49336 2/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.32
RECQL P46063 1/20 0.32
KMT2A Q03164 1/20 0.32
NFKB1 P19838 1/20 0.31
ADORA2A P29274 1/20 0.31
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949600 0.89 PDGFRB (0.50) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL17662099 0.88 PDGFRB (0.37) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949301 0.87 TP53 (0.37) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949316 0.83 RAB9A (0.36) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949340 0.83 PDGFRB (0.36) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949283 0.83 PDGFRB (0.45) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949294 0.83 KIT (0.47) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949298 0.82 PDGFRB (0.36) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949228 0.81 SLC2A1 (0.36) NPC1RAB9ANOD1TP53MAPT
SCHEMBL12336289 0.79 PDGFRB (0.56) PDGFRBKITPDGFRACDK11BFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.